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Pseudomonas aeruginosa plays an important role in chronic lung infections among patients with cystic fibrosis (CF) through its
ability to form antibiotic-resistant biofilms. In P. aeruginosa, biofilm development and the production of several virulence fac-
tors are mainly regulated by the rhl and las quorum-sensing (QS) systems, which are controlled by twoN-acyl-homoserine lac-
tone signal molecules. In a previous study, we discovered an original QS inhibitor,N-(2-pyrimidyl)butanamide, called C11,
based on the structure of C4-homoserine lactone, and found that it is able to significantly inhibit P. aeruginosa biofilm forma-
tion. However, recent data indicate that P. aeruginosa grows under anaerobic conditions and forms biofilms in the lungs of CF
patients that are denser andmore robust than those formed under aerobic conditions. Our confocal microscopy observations of
P. aeruginosa biofilms developed under aerobic and anaerobic conditions confirmed that the biofilms formed under these two
conditions have radically different architectures. C11 showed significant dose-dependent antibiofilm activity on biofilms grown
under both aerobic and anaerobic conditions, with a greater inhibitory effect being seen under conditions of anaerobiosis. Gene
expression analyses performed by quantitative reverse transcriptase PCR showed that C11 led to the significant downregulation
of rhlQS regulatory genes but also to the downregulation of both lasQS regulatory genes and QS system-regulated virulence
genes, rhlA and lasB. Furthermore, the activity of C11 in combination with antibiotics against P. aeruginosa biofilms was tested,
and synergistic antibiofilm activity between C11 and ciprofloxacin, tobramycin, and colistin was obtained under both aerobic
and anaerobic conditions. This study demonstrates that C11 may increase the efficacy of treatments for P. aeruginosa infections
by increasing the susceptibility of biofilms to antibiotics and by attenuating the pathogenicity of the bacterium.
Pseudomonas aeruginosa is the most common opportunisticGram-negative bacterium found in nosocomial and life-
threatening infections, such as pneumonia and septicemia, in im-
munocompromised patients (1). More notoriously, P. aeruginosa
is also the main pathogen in patients with cystic fibrosis (CF),
playing an important role in progressive lung destruction and the
subsequent respiratory failure, and is thus responsible for high
rates of morbidity and mortality (2).
The pathogenesis of chronic P. aeruginosa infections is mainly
due to the capacity of P. aeruginosa to form biofilms, which are
structured communities of bacteria encased in a self-produced
polymericmatrix, during the infection process (3). This adds to its
resistance to many antibiotics through a naturally lower outer
membrane permeability and many adaptive mechanisms when it
is growing as a biofilm (4, 5), making it difficult to eradicate in-
fections by conventional antibiotherapy since bacterial cells living
as biofilms are more tolerant toward antibiotics than their plank-
tonic counterparts (6). Hence, novel targets are needed to combat
biofilm infections. One of them could be the bacterial quorum-
sensing (QS) communication system. It has been shown that the
QS system plays a key role in orchestrating the expression ofmany
P. aeruginosa virulence factors (7), such as exoproteases, sidero-
phores, exotoxins, and several secondary metabolites, and partic-
ipates in the development of biofilms (8).
QS is a regulatory mechanism that enables bacteria to make
collective decisions with respect to the expression of a specific set
of genes. P. aeruginosa possesses three QS systems, las, rhl and
2-heptyl-3-hydroxy-4-quinolone, the last of which is referred to
as the Pseudomonas quinolone signal (PQS). Each of these QS
systems consists of one transcriptional regulator, LasR, RhlR, or
PqsR, respectively, and their associated signalingmolecules,N-(3-
oxo-dodecanoyl)-L-homoserine lactone (3-oxo-C12-HSL),N-bu-
tanoyl-L-homoserine lactone (C4-HSL), and PQS, respectively
(9). The N-acyl-homoserine lactone (HSL) signaling molecules
have been well studied and are synthesized by the autoinducer
enzymes LasI and RhlI for the las and rhlQS systems, respectively
(10). PQS synthesis requires the expression of multiple operons,
one of which is pqsABCDE (11). When a certain threshold con-
centration of signaling molecules is reached, binding to receptor
molecules is promoted and the activated complex forms dimers or
multimers, which in turn act as transcriptional regulators on tar-
get virulence genes. The las and rhl QS systems are hierarchically
arranged, with the las system being at the top of the signaling
cascade and positively regulating expression of the rhl system.
Both are required for all virulence determinants (12), and to-
gether, these systems control 6 to 11%of theP. aeruginosa genome
(13). The PQS system also plays a significant role in the transcrip-
tion of multiple P. aeruginosa virulence genes (14) and is inter-
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twined in the P. aeruginosaQS hierarchy, with its production and
bioactivity requiring the las and rhlQS systems, respectively (15).
P. aeruginosa extracellular quorum-sensing signal molecules
have been detected in the sputum and lungs of infected CF pa-
tients (16, 17), and many studies have shown that P. aeruginosa
mutants lacking functional QS systems form biofilms with a dras-
tically altered structure and exhibit significantly reduced virulence
in comparison with the biofilm structures and virulence of P.
aeruginosa strains with functional QS systems (8, 18). Therefore,
the QS system constitutes a highly attractive target for novel ther-
apeutics that may be developed. There are basically three different
points of attack in the QS systems of Gram-negative bacteria: the
signal generator, the signal molecule, and the receptor protein.
The last one has been the most intensively investigated, which has
been done with HSL analogs able to block the QS receptor site by
antagonism. In recent years, a large variety of synthetic HSL ana-
logs and natural product (i.e., furanone) libraries have been pro-
posed, and a number of QS inhibitors (QSIs) have shown prom-
ising results in studies conducted in vitro and sometimes in
experimental animal models of infection (19–21).
However, no QSI has been introduced on the market, and
therefore, we looked into new approaches by considering infor-
mation presented in the literature. The first concerned the pre-
dominance of C4-HSL in the lungs of CF patients and led to our
previous discovery of an original QSI, N-(2-pyrimidyl)butana-
mide, called C11, which is based on the structure of C4-HSL and
which is able to significantly inhibit P. aeruginosa biofilm forma-
tion in a dose-dependentmanner in the absence of cytotoxicity for
lung cells (22). Second, many studies have considered that P.
aeruginosa grows in an anaerobic environment in the lungs of
infected CF patients (23–25). In contrast to aerobic in vitro bio-
films, P. aeruginosa biofilms in CF patient lungs grow in stagnant
mucus, and recent data have revealed that this environment is
anaerobic and favors the production of the viscous exopolysac-
charide alginate (24).Meanwhile, it has been shown thatP. aerugi-
nosa forms biofilms that are denser andmore robust under anaer-
obic than aerobic conditions, thus calling into question many
previous works that were performed on biofilms grown under
aerobic conditions (23).
Actually, intensive antipseudomonal treatment has greatly im-
proved the prospects of patients with CF. However, high doses of
antibiotics, most commonly used in combination, lead to signifi-
cant side effects for the patients, as well as the emergence of bac-
terial strains resistant to these antibiotics. Therefore, the use of
molecules like QSIs to attenuate bacterial pathogenicity rather
than planktonic bacterial growth is attractive. However, little is
known about the relationship between the antibiofilm effect of
QSIs and the susceptibility of biofilms to antibiotics.
In order to expand our preliminary results (22), the present
study investigated the effects of the new QSI C11 on P. aeruginosa
biofilms placed under both aerobic and anaerobic conditions and
evaluated the relationship between its antibiofilm activity and the
expression of QS regulatory and QS-regulated genes. Finally, the
susceptibility of biofilms grown under aerobic and anaerobic con-
ditions to C11 in combination with conventional systemic (cipro-
floxacin, ceftazidime), topical (colistin), or systemic/topical (to-
bramycin) antibiotics used in P. aeruginosa lung infections was
analyzed.
MATERIALS AND METHODS
Chemicals. Ciprofloxacin, tobramycin, ceftazidime, colistin, and all
chemicals used for C11 and C4-HSL synthesis were obtained from Sigma-
Aldrich (Saint-Quentin-Fallavier, France).
C11 [N-(2-pyrimidyl)butanamide] was prepared by condensation of
butyryl chloride with 2-aminopyrimidine (in pyridine). The reaction
mixture was stirred under reflux for 30min. After the mixture was cooled
at room temperature, it was filtered and the resulting solution was evap-
orated under reduced pressure. The crude product was washedwith water
and recrystallized from ethanol to obtain colorless needles with a melting
point of 103°C at 60% yield. The compound was characterized by its 1H
nuclear magnetic resonance (NMR) and infrared (IR) spectra.
N-(2-Pyrimidyl)butanamide: molecular weight, 165 g/mol; melting
point, 103°C; 1HNMR (CDCl3),  (parts per million) 8.63, 2H, d (J 4.9
Hz)H4=, H6=; 8.40, 1Hbr,NH; 7.01 1H, t (J 4.85Hz)H5=; 2.75, 2H, t (J
7.40 Hz), CH2OCO; 1.81, 2H, m, CH2; 1.05, 3H, t, CH3; IR (KBr) 
(centimeters1): 3,400, 3,218, 3,074, 3,001, 2,961, 2,902, 2,873, 1,685,
1,583, 1,525, 1,446.
C4-HSLwas synthesized following the procedure previously described
(26) and was characterized by its 1H NMR and IR spectra.
All compounds tested were dissolved at the appropriate concentra-
tions in sterile distilled water.
Bacterial strain, culturemedia, andgrowth conditions.P. aeruginosa
PAO1 was obtained from the Institute Pasteur collection (Paris, France).
The strain was frozen and kept at80°C. Before each experiment, 2 sub-
cultures were prepared on Trypticase soy agar (bioMérieux, Craponne,
France) and incubated under aerobic conditions at 37°C for 24 h. Bacterial
suspensions were freshly prepared in sterile distilled water before each
experiment.
The bacterial enumerations were done on Trypticase soy agar. The
antimicrobial susceptibility tests were performed in Trypticase soy broth.
The basic medium used for biofilm formation (BBM), modified from the
medium described by Campanac et al. (27), containedMgSO4·2H2O (0.2
g/liter), FeSO4·7H2O (0.0005 g/liter), anhydrous Na2HPO4 (1.25 g/liter),
KH2PO4 (0.5 g/liter), (NH4)2SO4 (0.1 g/liter), and glucose (0.05 g/liter)
(Sigma-Aldrich, Saint-Quentin-Fallavier, France).
Control of planktonic growth.Liquid cultures ofP. aeruginosaPAO1,
inoculated at about 102 CFU/ml, were performed in BBMor in Trypticase
soy broth in a neutral glass tube. The tubeswere incubated at 37°C and 200
rpm using an orbital shaker (New Brunswick Scientific, Edison, NJ, USA)
for 48 h. Growth wasmonitored bymeasuring the optical density (OD) at
640 nm (OD640) at 6, 24, and 48 h.
Susceptibility testing of planktonic cells. The MIC and minimum
bactericidal concentration (MBC) of C11 and each antibiotic against P.
aeruginosa were determined using the broth microdilution method ac-
cording to the guidelines of the Clinical and Laboratory Standards Insti-
tute (CLSI) (28). Briefly, 100 l of C11 or antibiotics was loaded into the
wells of a sterile 96-well microtiter plate and subjected to 2-fold serial
dilutions with Trypticase soy broth (bioMérieux, Craponne, France) to
achieve final concentrations ranging from 128 to 0.125g/ml. A bacterial
suspension was prepared in sterile distilled water and adjusted to an
OD640 of 0.150, corresponding to a concentration of 10
8 CFU/ml. The
microtiter plates were inoculated using a multipoint inoculator (Denley;
Mast Diagnostics, Bootle, United Kingdom) to obtain a final concentra-
tion of 106 CFU/ml. Cell suspensions were added to all wells except the
outer wells, which were used as sterility controls. Growth wells (with bac-
teria and without test solution) were also included. The plates were pre-
pared in triplicate and then incubated at 37°C for 24 h. The MIC was
determined as the lowest concentration of test solution that inhibited the
visible growth of the tested microorganism.
TheMBCwas determined by removing 100-l aliquots from eachwell
without visible growth and then spread plating the aliquots onto Trypti-
case soy agar. The plates were incubated at 37°C for 24 h. The MBC was
defined as the lowest concentration of test compound that did not permit
any visible growth on the appropriate agar plate during the incubation
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period (99.9% of the bacteria were killed). Each concentration of the
tested compounds was tested in triplicate.
C11 antibiofilm activity under aerobic and anaerobic conditions.
The biofilm was assayed by use of the model developed by Khalilzadeh et
al. (22) with fewmodifications. Briefly, biofilms were developed in a ster-
ile 24-well cell culture plate, each well of which contained 1 ml of BBM
(2 solution) and 1 ml of sterile distilled water (control) or test com-
pound solution (C11) prepared at different concentrations in sterile dis-
tilled water (final concentrations, 8 to 1 g/ml). The highest concentra-
tion of C11 tested (8 g/ml) corresponded to 50 M. The bacterial
inoculum was prepared by dilution in sterile distilled water of an over-
night culture of PAO1 to an OD640 of 0.15, corresponding to a bacterial
density of 108 CFU/ml. The inoculum then underwent 10-fold serial di-
lutions (from 101 to 106), and 100 l of the 106 dilution (equivalent
to 102 CFU/ml) was added to each well. The plates were then incubated at
37°C. After 2, 4, 6, 20, and 24 h of incubation, the wells were rinsed twice
with sterile distilled water, and the medium (BBM with or without C11)
was replaced.
For the biofilms developedunder anaerobic conditions, BBMwas sup-
plemented with 1% KNO3 (Sigma-Aldrich, Saint-Quentin-Fallavier,
France) as previously recommended (23). Between eachmedium renewal,
the plates were placed in a Mart anaerobic jar (Mart Microbiology B.V.,
Netherlands) and then flushed with a gas mixture (80% N2, 10% CO2,
10%H2) using aMart Anoxomat system (MartMicrobiology B.V., Neth-
erlands) before incubation at 37°C.
After 48 h of incubation, biofilms were observed by confocal laser
scanning microscopy (CLSM). For the quantification of adherent cells,
the wells were rinsed twice with sterile distilled water, and the cells at the
bottoms of the wells were scraped with a sterile spatula and placed into 1
ml of sterile distilled water. Harvested biofilm samples were disaggregated
by vortexing vigorously for 2 min and by sonication (VibraCell 72441;
Bioblock Scientific) at 45W for 5 s and then analyzed by cell culture (CFU
method) and by real-time quantitative PCR (qPCR).
CLSM. Noninvasive confocal imaging of the biofilms that had been
incubated for 48 h was accomplished with a confocal visible Leica DMR
upright TCS SP2 AOBS microscope (Leica Microsystems, Wetzlar, Ger-
many) fitted with water-immersion dipping lenses (40HCXApo objec-
tive; numerical aperture, 0.8). Specimens were stained using the stain
from a LIVE/DEAD BacLight bacterial viability kit (Invitrogen, Cergy-
Pontoise, France) for microscopy according to the manufacturer’s in-
structions. An excitation wavelength of 488 nmwas used, and the fluores-
cence emitted at between 500 and 540 nm for SYTO 9 and at 543 nm for
propidium iodide was recorded. The biofilm structure was analyzed in
duplicate by taking a series of horizontal sections, each of which was 0.5
m thick. Digital images were processed using Leica confocal software
Lite (Leica Microsystems).
Quantification of adherent cells by cell culture (CFU method).
When necessary, logarithmic dilutions of harvested biofilm samples were
performed in sterile distilled water in order to decrease the numbers of
CFU to between 30 and 300 per plate. Aliquots of bacterial suspensions
were then plated out on Trypticase soy agar plates. After 24 h of incuba-
tion at 37°C, the numbers of viable CFU for triplicate wells were averaged
and subjected to logarithmic transformation. Following this protocol, the
detection and quantification limits were fixed at, respectively, 1 CFU/ml
and 30 CFU/ml (equivalent to 4 CFU/cm2).
Quantification of adherent cells by qPCR. Bacterial DNA of the har-
vested biofilm samples was extracted using a QIAamp DNA stool minikit
(Qiagen, Courtaboeuf, France) according to the manufacturer’s instruc-
tions. Extraction was performedwith 200l of bacterial suspension (con-
trol or samples). The extractedDNAwas eluted in 200l of elution buffer
and immediately stored at 20°C. The primers were designed using
Primer Express (version 3.0) software (Applied Biosystems, Foster City,
CA, USA), and the sequences were as follows: for the rhlR forward primer,
5=-AACGCGAGATCCTGCAATG-3=, and for the rhlR reverse primer, 5=-
GCGCGTCGAACTTCTTCTG-3=. The primer sequences were subjected
to a BLAST analysis against the P. aeruginosa PAO1 genome sequence to
eliminate the possibility of nonspecific binding. qPCR was carried out
using the IQ SYBR green supermix (Bio-Rad, Marnes-la-Coquette,
France) with a 25-l reaction mixture containing 12.5 l of 2 IQ SYBR
green supermix, 0.2 M each forward and reverse primer, and 5 l of
extracted DNA. qPCRwas performed using an iCycler IQ5 real-time PCR
detection system (Bio-Rad, Marnes-la-Coquette, France) and the follow-
ing cycling parameters: an initial denaturation at 95°C for 3min, followed
by 50 cycles of 95°C for 10 s, 60°C for 30 s, and 72°C for 30 s. Depending
on the melting temperature (Tm) of a specific amplicon, the melt curve
identifies a characteristic Tm that can distinguish between amplicons dif-
fering by only a single base. For our study, a melt curve analysis was
performed immediately after amplification at 95°C for 1min and 55°C for
1 min, followed by 81 repeats of heating for 10 s starting at 55°C and
increasing in 0.5°C increments. Negative controls (RNase-free water)
were added in each assay.
In order to construct standard curves, three control biofilms were
scraped and the number of CFUper square centimeter of each biofilmwas
determined by cell culture. Then, 10-fold dilutions of each biofilm were
made with sterile distilled water and bacterial DNA was extracted from
each dilution. The threshold cycle (CT) values of each dilution amplified
in triplicate were plotted as a function of the logarithm of the starting
quantity of P. aeruginosa (number of CFU per square centimeter). Stan-
dard curves were then used to determine the starting quantity of PAO1
biofilms in equivalent numbers of CFU per square centimeter. The slope
(s) of the standard curve were used to determine the PCR efficiency (E) in
conformity with E 10(1/s) 1 (29). Thus, a standard curvewith a slope
of 3.33 corresponded to a reaction with an efficiency value of 100%.
The quantification limit of the qPCR corresponded to 101 equivalent
CFU/cm2.
Gene expression. The effects of C11 and C4-HSL (used as a positive
control) on gene expression in biofilms were tested by adding into each
well of a sterile 24-well cell culture plate 1ml of 2BBMand 1ml of sterile
distilled water (control) or 1 ml of test compound solution (C11 or C4-
HSL) prepared in sterile distilled water (final concentration, 4 g/ml).
Then, biofilm formation was performed as described above for the test of
theC11 antibiofilmactivity under aerobic and anaerobic conditions. After
48 h of incubation, wells were rinsed twice with sterile distilled water, and
the cells at the bottoms of the wells were scraped with a sterile spatula and
placed into 1 ml of RNAprotect Bacteria reagent (Qiagen, Courtaboeuf,
France) for immediate RNA stabilization.
Total RNA of harvested biofilm samples was extracted using the
RNeasy minikit (Qiagen, Courtaboeuf, France) according to the manu-
facturer’s instructions, and a supplementary DNase digestion step was
performed with an RNase-free DNase set (Qiagen, Courtaboeuf, France).
A preliminary phase of destruction of the bacterial envelope was per-
formed by incubation in a solution of 1 mg/ml of lysozyme for 10 min at
room temperature. The primers and probes for the genes rhlR (PA3477),
rhlI (PA3476), lasR (PA1430), lasI (PA1432), rhlA (PA3479), and lasB
(PA3724) were designed with Primer Express software (Applied Biosys-
tems, Foster City, CA, USA) and were specific for P. aeruginosa PAO1
(NCBI GenBank). The rpoD (PA0576) gene was used as a control for
standardization. All primers and probes were purchased from Life Tech-
nologies (Saint-Aubin, France) (Table 1). The probes were labeled with
the reporter dye 6-carboxyfluorescein (6-FAM) at the 5= end and the
quencher 6-carboxytetramethylrhodamine (TAMRA) at the 3= end.
Quantitative reverse transcriptase PCR (qRT-PCR) was carried out using
an iTaq universal probes one-step kit (Bio-Rad, Marnes-la-Coquette,
France) with a 25-l reaction mixture containing 12.5 l of 2 iTaq
universal probes reaction mix, 0.6 l of iScript advanced reverse trans-
criptase, 200 nM each forward and reverse primer, 400 nM fluorescently
labeled probe, and 5l of extracted RNA. qRT-PCRwas performed using
an iCycler IQ5 real-time PCR detection system (Bio-Rad, Marnes-la-
Coquette, France) under the following conditions: incubation at 50°C for
10 min (reverse transcription reaction) followed by an activation step at
Furiga et al.
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95°C for 5 min and then 45 cycles of amplification with denaturation at
95°C for 10 s and annealing/extension at 60°C for 30 s. Negative controls
(RNase-free water) were added in each assay.
To determine the impact of the test compound on gene expression in
biofilms, each biofilm condition (C11 treatment, C4-HSL treatment, and
control treatment) was tested in triplicate, and the RNA was extracted
from each triplicate biofilm. Then, each extracted RNA was amplified in
triplicate and the means of the CT values were used for further analysis.
For each sample, the mean of the CT values obtained for a given gene (CT
gene) was normalized to the mean of the CT values obtained for the rpoD
gene (CT rpoD) amplified from the same sample at the same time. To
quantify the fold change in gene expression, we used a relative quantifica-
tion in which the expression levels of genes in treated biofilms were com-
pared to the expression levels of genes in control biofilms using the fol-
lowing formula: 2CT, where CT CT gene CT rpoD and CT
CT for the treated biofilm CT for the control biofilm.
Antibiofilm activity of C11 in combinationwith antibiotics.Biofilm
formation was performed as described above for the test of the C11 anti-
biofilm activity under aerobic and anaerobic conditions. At time zero
(T0), 100 l of the bacterial inoculum was added to each well of a sterile
24-well cell culture plate. For control biofilms and biofilms treated with
C11 alone, 1 ml of 2 BBM with, respectively, 1 ml of sterile distilled
water (control) or 1ml of C11 solution (1g/ml, C11 alone) was added to
the wells at T0. After 2, 4, 6, 20, and 24 h of incubation at 37°C, the wells
were rinsed and the medium (BBM with or without C11) was renewed.
For biofilms treated with antibiotics alone, 1 ml of 2 BBM with 1 ml of
sterile distilled water was added to the wells at 0, 2, 4, 6, and 20 h, and then
at 24 h the medium was replaced with 1 ml of 2 BBM with 1 ml of
antibiotic solution. For biofilms treated with a C11-antibiotic combina-
tion, 1 ml of 2 BBMwith 1 ml of C11 solution was added to the wells at
0, 2, 4, 6, and 20 h, and then at 24 h themediumwas replaced by 1ml of 2
BBM with 1 ml of a solution containing C11 and antibiotics. For all con-
ditions, biofilms were analyzed at 48 h by confocal laser scanning micros-
copy, and the number of adherent cells was quantified by theCFUmethod
and qPCR.
Statistical analysis. The Student t test was used to calculate the signif-
icance of the difference between the mean effects of a given compound
and those for the control group. For each assay, all determinations were
carried out in triplicate from three independent experiments. Statistically
significant values were defined as a P value of	0.05,	0.01, or	0.001.
RESULTS
Effects of C11 on growth of planktonic cells. Suspensions of P.
aeruginosa cells were made in Trypticase soy broth, as a positive
control, and in BBM and incubated at 37°C for 48 h under agita-
tion in order to limit biofilmdevelopment. Planktonic growthwas
monitored after 6, 24, and 48 h (Table 2). As expected, in Trypti-
case soy broth, the OD640 increased strongly with time up to
2.984 
 0.010. In contrast, no visible growth occurred in BBM,
with the OD640 reaching only 0.034
 0.002 after 48 h of incuba-
tion.
Determination of the MICs and MBCs of C11 and antibiotics
against P. aeruginosa was therefore performed in Trypticase soy
broth (Table 3). No bactericidal activity was obtained for C11 at
the highest concentration tested of 128g/ml, corresponding to a
molarity of greater than 500 M. In contrast, the antibacterial
activities of all the antibiotics tested against P. aeruginosa showed
low MIC and MBC values.
Antibiofilmactivity ofC11under aerobic andanaerobic con-
ditions. In order to promote the growth of adherent P. aeruginosa
bacteria and not simple cell adhesion and to produce a more ac-
curate model with a monospecies structured biofilm for in vitro
purposes, the wells of a sterile 24-well cell culture plate were inoc-
ulated with a low bacterial inoculum and BBM was renewed after
2, 4, 6, 20, and 24 h of incubation. After 48 h, control biofilms
observed by confocal microscopy and developed under aerobic
and anaerobic conditions clearly showed a typical biofilm struc-
ture (Fig. 1) and consisted of an average of 5.79
 0.04 and 6.33

0.12 log CFU/cm2, respectively (Fig. 2). These results and the
demonstration that there was no visible planktonic growth in
BBM bring out that biofilms formed in microplate wells result
only from the growth of the adhered bacteria.
Confocal microscopy of control biofilms developed for 48 h at
37°C under aerobic or anaerobic conditions showed that they had
very different structures (Fig. 1). Biofilms developed under aero-
bic conditions were characterized by the formation of typical mi-
crocolonies with more bacteria at the biofilm base (thickness,
30.13 m; Fig. 1A and A=). Biofilms grown under anaerobic con-
ditions (Fig. 1B and B=) were thicker (35.15 m) and more com-
pact than biofilms grown under aerobic conditions, and the bac-
teria were distributed more uniformly over the well surface.
Moreover, the quantification of adherent cells by cell culture of
these two control biofilms showed that biofilms grown under an-
aerobic conditions contained significantly more P. aeruginosa
bacteria than ones grown under aerobic conditions (Fig. 2).
The activity of C11 on P. aeruginosa biofilm development was
tested under aerobic and anaerobic conditions (Fig. 1C andD and
TABLE 1 Primers and TaqMan probes used to amplify genes by quantitative reverse transcriptase PCR
Gene
Sequence
Forward primer Reverse primer Probea
rhlR AACGCGAGATCCTGCAATG GCGCGTCGAACTTCTTCTG TGAGCATCTCCGAGAGCACGGT
rhlI GCAGCTGGCGATGAAGATATTC CGAACGAAATAGCGCTCCAT AGCCTGCAATGCGCCTGGTACCT
lasR GACCAGTTGGGAGATATCGGTTA TCCGCCGAATATTTCCCATA CAACTGCTCGGAAGCCAATGTGAACTTC
lasI GCCCCTACATGCTGAAGAACA CGAGCAAGGCGCTTCCT CTTCCCGGAGCTTCTGCACGGC
rhlA GGCGATCGGCCATCTG AGCGAAGCCATGTGCTGAT TCAACGAGACCGTCGGCAAATACCTG
lasB CGACAACGCGTCGCAGTA AGGTAGAACGCACGGTTGTACA TCGACGTGCACCACTCCAGCG
rpoD ACAAGATCCGCAAGGTACTGAAG CGCCCAGGTGCGAATC CGCCAAAGAGCCGATCTCCATGG
a The probes were labeled at the 5= end with 6-FAM and at the 3= end with TAMRA.
TABLE 2 Planktonic growth of P. aeruginosa in Trypticase soy broth or
BBM in tubesa
Medium
P. aeruginosa OD640 at:
6 h 24 h 48 h
Trypticase soy broth 0.001
 0.001 0.016
 0.004 0.034
 0.002
BBM 0.000
 0.001 2.162
 0.066 2.984
 0.010
a Growth was monitored by determination of the OD at 640 nm after 6, 24, and 48 h of
incubation at 37°C. Values are means
 standard deviations (n 3).
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2). Under both conditions, C11 showed significant inhibition of
biofilm formation in a dose-dependent manner (Fig. 2). For all
concentrations tested, the antibiofilm activity of C11 was signifi-
cantly greater on biofilms grown under anaerobic conditions,
with no biofilm development at 8 g/ml, than on biofilms grown
under aerobic conditions.
Effects of C11 on QS gene expression. The effects of C11 and
C4-HSL on the expression of QS regulatory genes (rhlR, rhlI, lasR,
lasI) andQS-regulated genes (rhlA, lasB) by P. aeruginosa biofilms
grown at 37°C for 48 h under aerobic and anaerobic conditions
were measured by quantitative RT-PCR (Fig. 3). The levels of QS
gene expressionwere normalized to the levels of rpoD gene expres-
sion and then compared with the levels of expression in control
biofilms. The compounds were tested at the same concentration
of 4g/ml because this was the highest concentration that did not
result in the complete inhibition of biofilm formation byC11 (Fig.
2). The quantification of adherent cells in biofilms grown in the
presence of 4g/ml of C4-HSL showed that they contained signif-
icantly (P 	 0.001, n  3) more bacteria than their respective
untreated biofilms: 6.41 
 0.08 and 7.19 
 0.08 log CFU/cm2
under aerobic and anaerobic conditions, respectively (data not
shown).
Under both biofilm development culture conditions, C4-HSL
led to the significant upregulation of QS regulatory genes belong-
ing to the rhl system (rhlR and rhlI), but no significant effect was
observed on las system genes (lasR and lasI). C4-HSL led to the
significant upregulation of the QS-regulated virulence genes rhlA
(rhamnolipid synthesis) and lasB (elastase synthesis), which are
mainly controlled by the rhl system, with fold changes in expres-
TABLE 3 Antimicrobial activities of C11 and antibiotics against
P. aeruginosaa
Compound MICb (g/ml) MBCc (g/ml)
C11 128 128
Ciprofloxacin 	0.125 	0.125
Tobramycin 1 2
Ceftazidime 4 8
Colistin 4 8
a Data are from three experiments.
b MIC, the concentration at which no bacterial growth was visible after 24 h of
incubation at 37°C.
c MBC, minimal bactericidal concentration (the concentration at which the number of
CFU was reduced by 99.9%).
FIG1 Confocal laser scanningmicroscopy images ofP. aeruginosa biofilms incubated at 37°C for 48 h under aerobic (A, A=, C) or anaerobic (B, B=, D) conditions
and then stained using stain from a LIVE/DEAD BacLight bacterial viability kit. (A, A=, B, B=) Control biofilms; (C, D) biofilms grown in the presence of C11 at
1 g/ml in the medium; (A=, B=) three-dimensional images of control biofilms.
FIG 2 Effect of C11 on P. aeruginosa biofilm development under aerobic and
anaerobic conditions at 37°C for 48 h. Results are expressed as the means and
standard deviations from triplicate experiments. Statistically significant differ-
ences (*, P	 0.05; ***, P	 0.001) between the test compound and its control
under aerobic or anaerobic conditions (n  3) and statistically significant
differences (††, P 	 0.01; †††, P 	 0.001) between the control or test com-
pound under aerobic conditions and the control or test compound under
anaerobic conditions (n 3) are indicated. ND, not detected.
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sion under aerobic and anaerobic conditions being 2.58 and 4.47,
respectively, for rhlA and 1.57 and 2.74, respectively, for lasB. In
contrast, C11 showed a significant downregulation of QS regula-
tory genes belonging to both the rhl and las systems, as well as the
QS-regulated virulence genes rhlA and lasB, with fold changes in
expression being between 2.75 for lasB and 18.84 for lasR
under aerobic conditions and between3.44 for lasI and32.96
for rhlR under anaerobic conditions.
Compared to the regulation of gene expression in biofilms
grown under aerobic conditions, the upregulation of gene expres-
sion induced by C4-HSL on biofilms developed under anaerobic
conditions was significantly (P	 0.05) greater for the rhlR, rhlA,
and lasB genes and the downregulation induced by C11 was sig-
nificantly (P	 0.05) higher for the rhlR, rhlI, rhlA, and lasB genes.
Antibiofilm activity of C11 in combination with antibiotics.
The activity of antibiotics on 24-h-old C11-untreated P. aerugi-
nosa biofilms (treated with an antibiotic alone) or C11-pretreated
P. aeruginosa biofilms (treated with the C11-antibiotic combina-
tion) grown under aerobic (Fig. 4A) and anaerobic (Fig. 4B) con-
ditions at 37°C for 48 h was analyzed.When it was tested, C11 was
added to the wells at T0 and at each medium renewal at 1 g/ml,
corresponding to the lowest concentration showing a significant
inhibitory effect on biofilms grownunder aerobic conditions (P	
0.05; reduction of 0.29 
 0.13 log CFU/cm2), in an attempt to
identify a possible synergy of activity when C11 was combined
with antibiotics. All antibiotics were added to the wells alone or in
combinationwithC11 after 24 h of biofilm formation. The highest
antibiotic concentrations tested were based on the average peak
levels achieved in serum 1 h after administration of a standard
single intravenous or oral dose: tobramycin, 8g/ml; ceftazidime,
32 g/ml; and ciprofloxacin, 2 g/ml. Colistin was tested at 32
g/ml, which is the median concentration in sputum after 1 h of
inhalation of the recommended dose of colistin. However, the
recommended concentrations of 8 g/ml for tobramycin and 32
g/ml for colistin led to high levels of inhibition of biofilm forma-
tion (greater than 3 log units; data not shown), and in order to
observe a possible synergy of activity, the concentrations of these
two antibiotics were reduced by half: the tobramycin concentra-
tion was reduced to 4 g/ml and the colistin concentration was
reduced to 16 g/ml.
We observed a loss of activity of antibiotics against P. aerugi-
nosa biofilms grown under aerobic conditions in comparison to
that against planktonic cells, with reductions of between 0.49 log
unit for ceftazidime and 2.27 log units for colistin, even though the
concentrations tested were 2- to 16-fold higher than the MBCs.
For ciprofloxacin, tobramycin, and colistin, the addition of C11
led to a significant (P	 0.001) increase in the antibiofilm activity
of the antibiotics, whereas for ceftazidime, the addition had no
significant effect. These two observations were also obtained with
biofilms developed under anaerobic conditions. However, the ef-
fects of the antibiotics tested alone on biofilms grown under an-
aerobic conditions were generally less than those on biofilms
grown under aerobic conditions, with reductions of between 0.30
FIG3 Relative expression of quorum-sensing genes (rhlR, rhlI, lasR, lasI, rhlA,
lasB) measured by quantitative reverse transcriptase PCR from P. aeruginosa
biofilms untreated (control) or treated with C4-HSL (4 g/ml) or C11 (4
g/ml). Biofilms were grown at 37°C for 48 h under aerobic or anaerobic
conditions. The levels of QS gene expression were normalized to the level of
rpoD gene expression and then compared with the level of expression by con-
trol biofilms. Results are expressed as the means and standard deviations from
triplicate experiments. Statistically significant differences (**, P 	 0.01; ***,
P	 0.001) between the test compound and its control are indicated (n 3).
FIG 4 Effect of C11 and antibiotics, tested alone or in combination, on P.
aeruginosa biofilms grown under aerobic (A) and anaerobic (B) conditions at
37°C for 48 h. C11 (1g/ml) was added to the wells at T0. Ciprofloxacin (CIP;
2 g/ml), tobramycin (TOB; 4 g/ml), ceftazidime (CAZ; 32 g/ml), and
colistin (CST; 16 g/ml) were tested on 24-h-old C11-untreated biofilms
(treated with antibiotics alone) or C11-pretreated biofilms (treated with the
C11-antibiotic combination). Quantification of adhered cells was carried out
after 48 h of incubation by cell culture (the CFU method; log number of CFU
per square centimeter) and by qPCR (equivalent log number of CFU per
square centimeter). Results are expressed as themeans and standard deviations
from triplicate experiments. Statistically significant differences (*,P	 0.05; **,
P	 0.01; ***, P	 0.001) between the test compound and its control (n 3),
measured by CFU enumeration or qPCR, and statistically significant differ-
ences (†, P 	 0.05; †††, P 	 0.001) between antibiotics tested alone and in
combination with C11, measured by CFU enumeration (n 3), are indicated.
NS, not significant; ND, not detected; NQ, not quantified.
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log unit for ceftazidime and 2.01 log units for colistin, while the
effects of the combination of the antibiotics with C11 were signif-
icantly greater on biofilms grown under anaerobic conditions.
On the other hand, when we compared the results obtained by
cell culture (number of CFU) and qPCR for antibiotics tested
alone on biofilms developed under both conditions, we observed
that the number of cells quantified by qPCR was always higher
than the number measured by culture, indicating that the activity
of the antibiotics was mainly bactericidal or at least led to cell
damage with no regrowth. This difference between the results of
the two quantification methods was not significant for C11, indi-
cating that its antibiofilm activity may be due to other mecha-
nisms, whichwas foreseeable, since it was tested at a concentration
considerably lower than its MIC/MBC (128 g/ml).
This hypothesis was confirmed by confocal microscopy obser-
vations, which revealed that P. aeruginosa biofilms treated with 1
g/ml of C11were thick and contained very few dead cells (in red)
relative to the number of living cells (in green) (Fig. 1C). In com-
parison, biofilms exposed to antibiotics alone had equivalent
thicknesses but their matrices showed many dead cells due to the
cell damage caused by the antibiotics (Fig. 5, left). In addition,
biofilms treated with the combination of antibiotics and C11 were
finer (Fig. 5, right), underlining the combination of actions, and
the number of dead cells was less than the number of live cells,
suggesting that C11 caused a modification in the structure of the
biofilms, causing the bacteria to revert to the planktonic state,
which allowed the antibiotics to exercise their activity. Damaged
cells were then removed by rinsing just before observations were
made by CSLM.
DISCUSSION
P. aeruginosa is known to grow in a sessile form in the lungs of
cystic fibrosis patients and to undergo a specific transition from
colonization to infection as a result of the expression of virulence
factors and host responses (4). Biofilm formation also induces a
loss of microbial susceptibility, leading to the use of higher con-
centrations of antibiotics and/or combinations (30, 31). There-
fore, we focused our study on the search for newmolecules that act
upstream to prevent biofilm formation, for molecules that poten-
tiate the action of conventional antibiotics on a structured bio-
film, or for molecules having both activities.
The quorum-sensing bacterial communication system in P.
aeruginosa plays a key role in the control of the production of
several virulence factors and in the regulation of biofilm forma-
tion (7, 8, 32, 33),making it a very attractive target in the search for
antibiofilm compounds. Many studies have been aimed at affect-
ing the synthesis of 3-oxo-C12-HSL because in vitro studies, per-
formed under aerobic conditions, have shown that this HSL is
required for biofilm differentiation and that the lasI gene is ex-
pressed in a large number of cells during the initial phase of bio-
film development. In contrast, the rhlI gene was considered to be
expressed in fewer cells, suggesting that C4-HSL plays no central
role in biofilm formation (34). In vivo, both HSLs have been de-
tected in the sputum of patients with cystic fibrosis (16, 17, 35).
However, it has been shownmore recently thatwhenP. aeruginosa
isolates from the sputum of CF patients are grown in biofilms,
they produce larger amounts of C4-HSL than 3-oxo-C12-HSL,
with the ratio being 3:1 (16). Moreover, it has been observed that
the amount of biofilm produced by a lasI mutant (deficient in
3-oxo-C12-HSL) of PAO1 strain PT5 is similar to the amount
produced by the wild type, whereas an rhlI mutant (deficient in
C4-HSL) produces 70% less biofilm than the wild type (36). On
the other hand, C4-HSL controls the production of rhamnolipids,
shown to be required for the maintenance of the biofilm architec-
FIG 5 Confocal laser scanning microscopy images of P. aeruginosa biofilms
incubated at 37°C for 48 h under aerobic conditions and treated with antibi-
otics alone (A to D) or with a combination of antibiotics and C11 (A= to D=).
(A) Ciprofloxacin at 2 g/ml; (A=) ciprofloxacin at 2 g/ml combined with 1
g/ml of C11; (B) tobramycin at 4 g/ml; (B=) tobramycin at 4 g/ml com-
bined with 1g/ml of C11; (C) ceftazidime at 32g/ml; (C=) ceftazidime at 32
g/ml combinedwith 1g/ml of C11; (D) colistin at 16g/ml; (D=) colistin at
16g/ml combinedwith 1g/ml of C11. Antibiotics were added in the screen-
ing model at 24 h, and C11 was added at T0. Biofilms were stained using stain
from a LIVE/DEAD BacLight bacterial viability kit.
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ture (37). All these observations suggest that C4-HSL also plays a
significant role in biofilm formation. Therefore, we previously
designed and then synthesized HSL analogs on the basis of the
structure of C4-HSL (22). Among them, N-(2-pyrimidyl)butana-
mide (called C11) showed significant inhibition of P. aeruginosa
biofilm formation in a dose-dependent manner.
Recent data indicate that the stagnant mucus of the CF airway
is anaerobic (24), suggesting that P. aeruginosa infection in CF
patients reflects biofilm formation and persistence in an anaerobic
environment. Yoon et al. (23) have demonstrated that P. aerugi-
nosa formsmore robust biofilms during anaerobic growth, andwe
confirmed this finding not only by cell culture (the CFUmethod)
and qPCR quantification but also by confocal microscopy obser-
vations (Fig. 1 and 2). Moreover, we confirmed the antibiofilm
effect of C11, which showed an amazing enhancement of biofilm
regulation under anaerobic conditions. This higher antibiofilm
activity of C11 under these conditions compared to that under
aerobic conditions confirms our preliminary hypothesis (22) that
C11 acts by inhibition of the rhl system.
Yoon et al. (23) also considered that themost efficient mode of
growth under anaerobic conditions required enzymes/proteins
that allowed P. aeruginosa to (i) utilize nitrate (NO3
) and nitrite
(NO2
) as terminal electron acceptors, (ii) influence the activity/
stability of denitrifying enzymes (OprF protein), and (iii) modu-
late the production (rhl QS system) and removal (nitric oxide
reductase) of toxic nitric oxide (NO), a by-product of anaerobic
respiration. Thus, we suggest that these pathways represent can-
didate targets for a novel suite of antimicrobials, founded on the
basis of the proposal that successful treatment of the disease may
require the disruption of anaerobic respiration within the anaer-
obic airwaymucus. These data provide onemore reason to search
for an inhibitor of the rhl system and, thus, to select analogs based
on the C4-HSL structure.
Moreover, in order to confirm that C11 exerts its activity on
biofilm formation via inhibition of the rhl system, we evaluated its
effect on the expression of QS regulatory and QS-regulated genes.
As expected, when C4-HSL was added, a significant increase in
rhlR and rhlI expression was observed, while no impact on lasR
and lasI expression was noted. In contrast, the addition of C11
induced a significant downregulation of regulatory genes belong-
ing to both the rhl and las systems (Fig. 3). So, it is likely that C11
reduced the production of bothC4-HSL and 3-oxo-C12-HSL. This
result is not surprising, as structure-activity relationship studies
have already revealed some interactions between the compound
C11 and the receptor protein LasR (22). As 3-oxo-C12-HSL is
required for biofilm differentiation (6), it is likely that C11, by
reducing the effects of both HSLs, not only leads to a reduction in
the total amount of biofilm formed but also affects its differenti-
ation. On the other hand, many of the virulence factors produced
by P. aeruginosa are regulated by theQS system (38). Among these
are rhamnolipids and elastase, whose synthesis partly depends on
the activation of the rhlA and lasB genes, respectively (39, 40).
Rhamnolipids and elastase are capable of degrading or inactivat-
ing important biological tissues and immune system components
(40, 41) and have been found to contribute to the virulence of P.
aeruginosa in clinical studies (42, 43). In our study, C11 led to a
significant inhibition of the expression of rhlA and lasB and so
could certainly contribute to the fight against P. aeruginosa patho-
genesis.
Concerning antibiotic activity, our results (Table 3 and Fig. 4)
confirm the loss of antibiotic susceptibility when P. aeruginosa is
grown as a biofilm. In addition, an important demonstration in
our work concerns the higher levels of resistance to antibiotics of
P. aeruginosa biofilms growing under anaerobic conditions. This
loss of biofilm susceptibility to antimicrobial treatments is well-
known and is often the result of a combination of transfer limita-
tion, the consumption/neutralization of the antibiotics by biofilm
matrix components, and drastic modifications in gene expression
and cell physiology (31). This process must thus be considered
ubiquitous, as the various antibiotics tested have different cell tar-
gets, i.e., peptidoglycan synthesis for ceftazidime (44), DNA syn-
thesis for quinolones, and protein synthesis for tobramycin (45).
For colistin, the target is lipid A of the lipopolysaccharide (LPS) of
the outermembrane of Gram-negative bacteria (46). Thanks to its
positive charge, colistin interacts electrostatically with these mol-
ecules and competitively displaces divalent cations from them,
causing disruption of themembrane. This results in an increase in
cell wall permeability and, subsequently, cell death (47, 48). Other
combined effects are expected to produce lethality leading to rapid
bactericidal activity combined with a systemic toxicity. Thus,
colistin could be considered a biocide rather than an antibiotic.
The loss of activity on biofilms could be linked to its chemical
characteristics. Colistin is a cyclic lipodecapeptide, which is
strongly cationic and can be neutralized by the polyanionic ex-
opolysaccharides (49). In spite of this, our results underline the
fact that neither the bacterial target nor the antibacterial activity
(inhibition of growth or bactericidal activity) is discriminating for
the selection of antibiotics active against biofilms.
Because of the interest in C11 as aQS inhibitor, we combined it
with antibiotics (Fig. 4 and 5). As previously described, C11 had
no killing effect on a mature biofilm (22). The activities of antibi-
otics on 24-h-old C11-untreated or C11-pretreated biofilms were
therefore tested in order to demonstrate the effects of combina-
tion treatment. A dramatic increase in the antibiofilm activities of
the antibiotics was observed when C11 was combined with cipro-
floxacin, tobramycin, and, above all, colistin, which resulted in the
detection of no adherent cells. Surprisingly, in our study, C11 did
not restore the efficiency of ceftazidime against biofilms grown
under either aerobic or anaerobic conditions. For the other anti-
biotics tested, impairment of the QS system (i) led to a significant
modification of the biofilm matrix, resulting in poor interactions
with active molecules, which were thus able to reach their cell
targets, and/or (ii) maintained the intracellular machinery for an-
tibiotic efficiency. For colistin, the first hypothesis is more likely,
considering its cationic structure and its membrane target (50).
On the other hand, previous important work ofWagner et al. (51)
on the shift in gene expression between planktonic and sessile P.
aeruginosa cells showed that genes implicated in DNA replication,
recombination, modification, and repair could be considered to
be repressed in biofilm cells, which could explain the restoration
of ciprofloxacin activity when C11 is present. In the same way,
transcription and RNA processing and degradation were consid-
ered to be downregulated. For genes implicated in cell wall/LPS/
capsule production, the results are more difficult to interpret be-
cause of the balance between the genes whose expression was
promoted and repressed. Our observations by CLSM (Fig. 5) did
not reveal any modification of cell morphology, while the cell
damage cause by ceftazidime treatment is considered characteris-
tic of the damage induced by beta-lactam molecules, which con-
sisted of the elongation of specific cells (52), andmolecules such as
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tobramycin induced abnormal proteins that were even incorpo-
rated into the cell wall, resulting in an apparent loss of integrity
or elasticity and a rough appearance, as demonstrated by
atomic force microscopy observations (53). So, under our con-
ditions, the inhibition of C4-HSL did not allow ceftazidime to
reach its cellular target (periplasmic transpeptidases and carboxy-
peptidases) and/or to induce significant effects, given that pepti-
doglycan synthesis is involved in the cell division process.
These effects emphasizing the great therapeutic value of QSIs
in rendering biofilms more susceptible to antimicrobial com-
pounds have been previously observed and encouraged us to con-
duct the same type of experiment with combinations of com-
pounds. Hentzer et al. (54) demonstrated that, unlike untreated
biofilms, P. aeruginosa biofilms pretreated with the synthetic ha-
logenated furanone C-30 were easily killed by tobramycin treat-
ment. Similarly, P. aeruginosa biofilms were more sensitive to to-
bramycin when they were pretreated with either garlic extract or
extracts from Penicillium species (patulin and penicillic acid), all
of which inhibited the QS system, as judged from the findings of
DNA array-based transcriptomics (55, 56). Moreover, Chris-
tensen et al. (57) demonstrated that the furanone C-30, ajoene
from garlic, and horseradish juice extract exhibited QSI activity in
vitro and provided synergistic antimicrobial effects with tobramy-
cin in combination treatments initiated early after infection
against in vivo P. aeruginosa biofilms in a mouse model of an
intraperitoneal foreign-body infection. Unfortunately, these
compounds are unsuitable for human use: halogenated furanones
are unstable, fungal compounds are mycotoxins, and the active
components fromnatural sources exist at very low concentrations
(21). However, C11 is a stable compound that can be easily syn-
thesized in large quantities and is not cytotoxic to lung cells (22).
Thus, these data observed for in vivobiofilms are promising for the
development of a prophylactic or early C11-antibiotic combina-
tion treatment strategy for patients with P. aeruginosa infections.
To date, only azithromycin (AZM), a macrolide antibiotic
known to be a QSI, has been gaining favor for the treatment of
chronic lung infections caused by P. aeruginosa due to the im-
proved outcomes seen in CF patients (58). The mechanisms of
action of AZM are multiple and may include an anti-inflamma-
tory effect, inhibition of alginate production, inhibition of protein
synthesis, and/or inhibition of the QS system and the associated
virulence factors that are produced (59). AZM was found to in-
hibit biofilm formation at a sub-MIC (2 g/ml), and this activity
was specific to the initial stages of biofilm formation, sincemature
biofilmswere not affected by the presence of 8g/ml ofAZM(60).
Moreover, AZM reduced the levels of production of both C4-HSL
and 3-oxo-C12-HSL (36). These data are comparable to those ob-
served for C11, suggesting its clinical efficacy. Concerning the
combination of AZMwith antibiotics, it was shown that the addi-
tion of AZM decreased the MICs of many antipseudomonal
agents (61), and synergistic activity in eradicating a 24-h-old P.
aeruginosa biofilm was observed only with the combination of a
high dose of AZM (256 g/ml) and ciprofloxacin (1 g/ml) (62).
In conclusion, it appears that C11, by reducing cell-to-cell sig-
nal production, interferes with biofilm formation at different lev-
els under both aerobic and anaerobic conditions, resulting in a
decrease in the levels of production of extracellular virulence fac-
tors, such as rhamnolipids and elastase, and also, in combination
with antibiotics, allowing the recovery of their antibacterial activ-
ity against P. aeruginosa biofilms. The use of original synthetic
molecules capable of interfering with biofilm development and
the expression of the associated virulence factors constitutes an
interesting alternative to the massive use of antibiotics and prom-
ises new approaches for the prevention and/or treatment of P.
aeruginosa infections. The clinical application of such molecules
should be considered further, as prophylactic or early treatment
with the combination of C11 and conventional antibiotics may
prevent the formation of highly resistant P. aeruginosa biofilms on
medical devices as well as in the lungs of CF patients before a
chronic infection is established. Moreover, C11 may improve the
outcomes of patients with P. aeruginosa infections by increasing
the efficacy of the antibiotics against biofilm-forming bacteria and
by attenuating the pathogenicity of the bacterium. Therefore, this
study should be continued to determine the best combination of
molecules effective against P. aeruginosa biofilms and to define
optimal conditions for further investigations in amurinemodel of
chronic lung infection.
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